1Parks WC, Wilson CL, Lopez -Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity[J] . Nat Rev lmmunol. 2004,4(8) :617 - 629.
2Shu H, Wong B, Zhou G, et al. Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells[J] .Biochem Biophys Res Commun. 2000,267 ( 1 ) : 345 - 349.
3Schneider F, Sukhova GK, Aikawa M, et al. Matrix -metalloproteinase - 14 deficiency in bone- marrow- derived cells promotes collagen accumulation in mouse atherosclerotic plaques[J] . Circulation. 2008, 117 (7) :931 -939.
8Virmani R, Burke AP, Farb A, et al. Pathology of the vulnerable plaque [J]. J Am Coll Cardiol,2006, 47 :C13 - C18.
9Blankenberg S, Rupprecht H J, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease[ J] . Circulation, 2003, 107 (12) : 1579 - 1585.
10Wu TC. Leu HB, Lin WT, et al. Plasma matrix matalloproteinasa -3 level is an independent prognostic factor in stable coronary artery disease[J]. Eur J Clin Invest, 2005,35 (9) : 537 - 545.
